MORRISTOWN, N.J., Sept. 27, 2019 /PRNewswire/ -- Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with
CONTRAVE is a prescription weight-loss medicine with patent protection until 2034. CONTRAVE works in two parts of the brain to help some adults control their eating, resulting in sustained weight loss. Contrave is indicated to help patients with a body mass index (BMI) of 30kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least on weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, to lose weight and maintain their weight loss.
"It is exciting to announce our second acquisition in as many days," said George Hampton, chief executive officer of Currax Pharmaceuticals LLC. "This acquisition bolsters our Branded portfolio and demonstrates that we are successfully executing on our business strategy to acquire clinically differentiated medicines with high potential for growth and extended IP life."
CONTRAVE was approved by FDA on September 10, 2014.
About Currax Pharmaceuticals LLC
Currax Pharmaceuticals LLC is a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs within the US market. Currax distributes a range of both Branded and generic pharmaceutical products, including Silenor®, Treximet®, Zohydro® ER with BeadTek®, the authorized generic of Treximet®, and now ONZETRA® Xsail®.
About Nalpropion, Inc.
Nalpropion is a biopharmaceutical company focused on the treatment of weight loss. CONTRAVE (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe, the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged release).
Important Safety Information for CONTRAVE
CONTRAVE can cause serious side effects of suicidal thoughts or actions. One of the ingredients in CONTRAVE is bupropion HCl. Bupropion has caused some people to have suicidal thoughts or actions or unusual changes in behavior, whether or not they are taking medicines used to treat depression. Bupropion may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment. If you already have depression or other mental illnesses, taking bupropion may cause it to get worse, especially within the first few months of treatment.
Stop taking CONTRAVE and call a healthcare provider right away if you, or your family member, have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempts to commit suicide; depression; anxiety; feeling very agitated or restless; panic attacks; trouble sleeping (insomnia); irritability; acting aggressive, being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); other unusual changes in behavior or mood.
While taking CONTRAVE, you or your family members should pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings and maintain communication with your healthcare provider. CONTRAVE has not been studied in and is not approved for use in children under the age of 18.
Do not take CONTRAVE if you:
Possible serious side effects of CONTRAVE:
Contact: George Jones, firstname.lastname@example.org, 862 579 2504
View original content:http://www.prnewswire.com/news-releases/currax-pharmaceuticals-llc-announces-the-acquisition-of-nalpropion-pharmaceuticals-inc-300926768.html
SOURCE Currax Pharmaceuticals LLC